

ASX ANNOUNCEMENT

20 January 2022

Rua shareholders approve acquisition of Zalm Therapeutics

20 January 2022 – Further to the previous announcement made by Cann Group Limited (ASX:CAN) (**Cann** or the **Company**) on 30 November 2021, Cann announced today that the acquisition of Zalm Therapeutics Limited (of which Cann holds 8.36% shares) by Rua Bioscience Limited (NZE:RUA) (**Rua**) was approved by Rua's shareholders yesterday. Details of the transaction are specified in Cann's previous announcement and in Rua's announcement yesterday to the New Zealand Stock Exchange.

Authorised for release by Geraldine Farrell, Company Secretary, Cann Group Limited.

For all media enquiries please contact:

Matthew Wright NWR Communications +61 451 896 420 matt@nwrcommunications.com.au

For all other information please contact:

Peter Crock
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Clive Fanning Head of Investor Relations Cann Group Limited +61 3 9095 7088

clive.fanning@canngrouplimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.

Learn more at: www.canngrouplimited.com | www.satipharm.com